FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168575500> ?p ?o ?g. }

• W3168575500 endingPage "102007" @default.
• W3168575500 startingPage "102007" @default.
• W3168575500 abstract "In the current coronavirus health crisis, inhaled bronchodilators(IB) have been suggested as a possible treatment for patients hospitalized. Patients with evidence of Covid-19 pneumonia worldwide have been prescribed these medications as part of therapy for the disease, an indication for which this medications could be ineffective taken on account the pathophysiology and mechanisms of disease progression. The main objective was to evaluate whether there is an association between IB use and length of stay. Primary end points were the number of days that a patient stayed in the hospital and death as a final event in a time to event analysis. Pneumonia severity, oxygen requirement, involved drugs, comorbidity, historical or current respiratory diagnoses and other drugs prescribed to treat coronavirus pneumonia were also evaluated. A descriptive, observational, cross-sectional study was performed in this tertiary hospital in Madrid (Spain). Data were obtained regarding patients hospitalized with Covid-19, excluding those who were intubated. The primary and secondary outcomes such as duration of hospitalization and death were compared in patients who received IB with those in patients who did not. 327 patients were evaluated, mean age was 64.4 ± 15.8 years. Median length of hospitalization stay was 10 days. Of them 292 (89.3%) overcame the disease, the remaining 35 died. Patients who had received IB did not have less mortality rate (odds ratio 0.839; 95% CI: 0.401 to 1.752) and less hospitalization period when compared with patients who did not received IB (odds ratio 1.280; 95% CI: 0.813 to 2.027). There was no significant association between IB use and recovery or death. Hypertension and diabetes were the most common comorbidities. The prevalence of chronic respiratory disease in our cohort was low (21.1%). Anticholinergics were the IB more frequently prescribed for Covid-19 pneumonia. Better response in patients treated with inhaled corticosteroids was not observed. Off-label indication of inhaled-bronchodilators for Covid-19 patients are common in admitted patients. Taken on account our results, the use of IB for coronavirus pneumonia apparently is not associated with a significantly patient's improvement. Our study confirms the hypothesis that inhaled bronchodilators do not improve clinical outcomes or reduce the risk of Covid-19 mortality. This could be due to the fact that the virus mainly affects the lung parenchyma and the pulmonary vasculature and probably not the airway. More researches are necessary in order to fill the gap in evidence for this new indication." @default.
• W3168575500 created "2021-06-22" @default.
• W3168575500 creator A5004951244 @default.
• W3168575500 creator A5005378862 @default.
• W3168575500 creator A5023387345 @default.
• W3168575500 creator A5030758252 @default.
• W3168575500 creator A5034670134 @default.
• W3168575500 creator A5035464561 @default.
• W3168575500 creator A5039838327 @default.
• W3168575500 creator A5044334282 @default.
• W3168575500 creator A5054512770 @default.
• W3168575500 creator A5055932285 @default.
• W3168575500 creator A5072199575 @default.
• W3168575500 creator A5075812440 @default.
• W3168575500 date "2021-08-01" @default.
• W3168575500 modified "2023-10-18" @default.
• W3168575500 title "Inhaled bronchodilators use and clinical course of adult inpatients with Covid-19 pneumonia in Spain: A retrospective cohort study" @default.
• W3168575500 cites W1978682645 @default.
• W3168575500 cites W2009717120 @default.
• W3168575500 cites W2012497891 @default.
• W3168575500 cites W2095580870 @default.
• W3168575500 cites W2157789635 @default.
• W3168575500 cites W2404364295 @default.
• W3168575500 cites W3001118548 @default.
• W3168575500 cites W3008827533 @default.
• W3168575500 cites W3009885589 @default.
• W3168575500 cites W3011610993 @default.
• W3168575500 cites W3012562222 @default.
• W3168575500 cites W3015498279 @default.
• W3168575500 cites W3016535995 @default.
• W3168575500 cites W3016785135 @default.
• W3168575500 cites W3017994966 @default.
• W3168575500 cites W3019714676 @default.
• W3168575500 cites W3024848265 @default.
• W3168575500 cites W3028759181 @default.
• W3168575500 cites W3030405955 @default.
• W3168575500 cites W3033304019 @default.
• W3168575500 cites W3034091913 @default.
• W3168575500 cites W3035093448 @default.
• W3168575500 cites W4210642183 @default.
• W3168575500 doi "https://doi.org/10.1016/j.pupt.2021.102007" @default.
• W3168575500 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8196225" @default.
• W3168575500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34129946" @default.
• W3168575500 hasPublicationYear "2021" @default.
• W3168575500 type Work @default.
• W3168575500 sameAs 3168575500 @default.
• W3168575500 citedByCount "3" @default.
• W3168575500 countsByYear W31685755002022 @default.
• W3168575500 countsByYear W31685755002023 @default.
• W3168575500 crossrefType "journal-article" @default.
• W3168575500 hasAuthorship W3168575500A5004951244 @default.
• W3168575500 hasAuthorship W3168575500A5005378862 @default.
• W3168575500 hasAuthorship W3168575500A5023387345 @default.
• W3168575500 hasAuthorship W3168575500A5030758252 @default.
• W3168575500 hasAuthorship W3168575500A5034670134 @default.
• W3168575500 hasAuthorship W3168575500A5035464561 @default.
• W3168575500 hasAuthorship W3168575500A5039838327 @default.
• W3168575500 hasAuthorship W3168575500A5044334282 @default.
• W3168575500 hasAuthorship W3168575500A5054512770 @default.
• W3168575500 hasAuthorship W3168575500A5055932285 @default.
• W3168575500 hasAuthorship W3168575500A5072199575 @default.
• W3168575500 hasAuthorship W3168575500A5075812440 @default.
• W3168575500 hasBestOaLocation W31685755001 @default.
• W3168575500 hasConcept C126322002 @default.
• W3168575500 hasConcept C156957248 @default.
• W3168575500 hasConcept C167135981 @default.
• W3168575500 hasConcept C187212893 @default.
• W3168575500 hasConcept C194828623 @default.
• W3168575500 hasConcept C201903717 @default.
• W3168575500 hasConcept C2777914695 @default.
• W3168575500 hasConcept C2779134260 @default.
• W3168575500 hasConcept C2779159551 @default.
• W3168575500 hasConcept C2780630273 @default.
• W3168575500 hasConcept C3008058167 @default.
• W3168575500 hasConcept C524204448 @default.
• W3168575500 hasConcept C71924100 @default.
• W3168575500 hasConcept C72563966 @default.
• W3168575500 hasConceptScore W3168575500C126322002 @default.
• W3168575500 hasConceptScore W3168575500C156957248 @default.
• W3168575500 hasConceptScore W3168575500C167135981 @default.
• W3168575500 hasConceptScore W3168575500C187212893 @default.
• W3168575500 hasConceptScore W3168575500C194828623 @default.
• W3168575500 hasConceptScore W3168575500C201903717 @default.
• W3168575500 hasConceptScore W3168575500C2777914695 @default.
• W3168575500 hasConceptScore W3168575500C2779134260 @default.
• W3168575500 hasConceptScore W3168575500C2779159551 @default.
• W3168575500 hasConceptScore W3168575500C2780630273 @default.
• W3168575500 hasConceptScore W3168575500C3008058167 @default.
• W3168575500 hasConceptScore W3168575500C524204448 @default.
• W3168575500 hasConceptScore W3168575500C71924100 @default.
• W3168575500 hasConceptScore W3168575500C72563966 @default.
• W3168575500 hasLocation W31685755001 @default.
• W3168575500 hasLocation W31685755002 @default.
• W3168575500 hasLocation W31685755003 @default.
• W3168575500 hasOpenAccess W3168575500 @default.
• W3168575500 hasPrimaryLocation W31685755001 @default.
• W3168575500 hasRelatedWork W1971557041 @default.
• W3168575500 hasRelatedWork W2101301140 @default.

• next